within Pharmacolibrary.Drugs.ATC.S;

model S01GA04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0004166666666666667,
    adminDuration  = 600,
    adminMass      = 0.05 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.028,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01GA04</td></tr><td>route:</td><td>nasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxymetazoline is an imidazoline derivative with sympathomimetic properties, primarily used as a topical nasal decongestant or in ophthalmic formulations to alleviate redness. It acts as an alpha-adrenergic agonist causing vasoconstriction of nasal mucosa and conjunctival blood vessels. Oxymetazoline is approved and commonly used today in both nasal spray and ophthalmic solutions for short-term relief of congestion and eye redness.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic model was identified in peer-reviewed literature for oxymetazoline in humans. Parameters estimated based on available non-compartmental data and analogous alpha-agonist drugs.</p><h4>References</h4><ol><li><p>Cartabuke, R, et al., &amp; Jatana, KR (2021). Topical Nasal Decongestant Oxymetazoline: Safety Considerations for Perioperative Pediatric Use. <i>Pediatrics</i> 148(5) –. DOI:<a href=&quot;https://doi.org/10.1542/peds.2021-054271&quot;>10.1542/peds.2021-054271</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34607935/&quot;>https://pubmed.ncbi.nlm.nih.gov/34607935</a></p></li><li><p>Zannikos, P, et al., &amp; Singh, J (2023). Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment. <i>Clinical pharmacokinetics</i> 62(9) 1315–1328. DOI:<a href=&quot;https://doi.org/10.1007/s40262-023-01273-z&quot;>10.1007/s40262-023-01273-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37402024/&quot;>https://pubmed.ncbi.nlm.nih.gov/37402024</a></p></li><li><p>Cartabuke, RS, et al., &amp; Tobias, JD (2019). Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. <i>The Laryngoscope</i> 129(12) 2775–2781. DOI:<a href=&quot;https://doi.org/10.1002/lary.27760&quot;>10.1002/lary.27760</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30786035/&quot;>https://pubmed.ncbi.nlm.nih.gov/30786035</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01GA04;
